Gimistotug Biosimilar – Anti-ACT35 antigen mAb – Research Grade from ProteoGenix; catalogue PX-TA2193; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Gimistotug Biosimilar, also known as Anti-ACT35 antigen mAb, is a cutting-edge therapeutic antibody that has been developed for the treatment of various diseases. This biosimilar is a highly specific and potent antibody that targets the ACT35 antigen, making it a valuable tool for researchers and clinicians alike.
Gimistotug Biosimilar is a monoclonal antibody (mAb) that is produced using recombinant DNA technology. It is a fully humanized IgG1 antibody with a molecular weight of approximately 150 kDa. The antibody consists of two heavy chains and two light chains, which are connected by disulfide bonds. The heavy chains contain the antigen-binding fragment (Fab), while the light chains contain the constant fragment (Fc).
The Fab region of Gimistotug Biosimilar is responsible for binding to the ACT35 antigen, while the Fc region is responsible for mediating effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). This dual functionality makes Gimistotug Biosimilar a potent therapeutic agent.
Gimistotug Biosimilar has been extensively studied and has shown promising results in various pre-clinical and clinical trials. Its main activity lies in its ability to specifically target and bind to the ACT35 antigen, which is overexpressed in various diseases such as cancer and autoimmune disorders.
Upon binding to the ACT35 antigen, Gimistotug Biosimilar triggers a series of immune responses, leading to the destruction of the target cells. This includes inducing apoptosis, activating immune cells, and recruiting other effector molecules to the site of action. This targeted approach minimizes the risk of off-target effects and reduces the potential for adverse reactions.
Furthermore, Gimistotug Biosimilar has also shown to have a longer half-life compared to other therapeutic antibodies, allowing for less frequent dosing and improved patient compliance.
Gimistotug Biosimilar has a wide range of potential applications in the field of medicine. Its main application is in the treatment of diseases that are characterized by the overexpression of the ACT35 antigen. This includes various types of cancer, such as breast, lung, and colon cancer, as well as autoimmune disorders like rheumatoid arthritis and multiple sclerosis.
Additionally, Gimistotug Biosimilar can also be used as a research tool in the development of new therapies and diagnostic methods. Its high specificity and potency make it a valuable tool for studying the role of the ACT35 antigen in different diseases and identifying potential therapeutic targets.
The future of Gimistotug Biosimilar looks promising, with ongoing research and development efforts focusing on expanding its applications and improving its efficacy. With its unique structure and mechanism of action, Gimistotug Biosimilar has the potential to revolutionize the treatment of various diseases and improve the lives of patients worldwide.
Gimistotug Biosimilar, also known as Anti-ACT35 antigen mAb, is a highly specific and potent therapeutic antibody that targets the ACT35 antigen. Its unique structure and mechanism of action make it a valuable tool for researchers and clinicians in the fight against various diseases. With ongoing research and development, Gimistotug Biosimilar has the potential to change the landscape of medicine and improve patient outcomes.
ProteoGenix catalogue number PX-TA2193. For research use only.
Target: Gimistotug Biosimilar – Anti-ACT35 antigen mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >95% by SDS-PAGE; Buffer: 0.01M PBS, pH 7.4; Applications: WB, ELISA.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Gimistotug Biosimilar – Anti-ACT35 antigen mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
